Berlin, Germany

Juergen Slapke

This inventor holds 1 USPTO granted patent. Top assignee: Humboldt-Universitaet Zu Berlin. Active years: 1989.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 1989

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Juergen Slapke: Innovator in Pharmaceutical Chemistry

Introduction

Juergen Slapke is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative research and development of new compounds.

Latest Patents

Juergen Slapke holds a patent for a novel compound titled "1-(2-hydroxyaryl)-alkane-1-on-oximes-procedure of preparation and use." This patent focuses on the development of 1-(2-hydroxyaryl)-alkane-1-on-oximes with desirable pharmacological properties. The new compounds are characterized by their pharmacologically valuable properties, including anti-asthmatic, anti-anaphylactic, antiphlogistic, antihypertensive, spasmolytic, antirheumatic, and antithrombotic potentials. They are applicable in both human and veterinary medicine for the treatment of asthma bronchiale, allergic diseases, inflammatory and rheumatic diseases, and thrombosis.

Career Highlights

Juergen Slapke is affiliated with Humboldt-Universität zu Berlin, where he has contributed to various research initiatives. His work has been instrumental in advancing the understanding of pharmacological compounds and their applications in medicine.

Collaborations

Some of his notable coworkers include Hans-Joachim Binte, who is deceased, and Tankred Schewe. Their collaborative efforts have further enriched the research environment at Humboldt-Universität zu Berlin.

Conclusion

Juergen Slapke's innovative work in pharmaceutical chemistry has led to the development of valuable compounds with significant therapeutic potential. His contributions continue to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…